Skip to main
DOCS
DOCS logo

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 37%
Hold 32%
Sell 5%
Strong Sell 5%

Bulls say

Doximity Inc. demonstrated strong growth, with its Point of Care (POC) and formulary offerings increasing by over 100% during the recent buying season, which signifies robust demand for its services among medical professionals. The company's shares have shown resilience, edging up 3.2% since September 8, reflecting positive investor sentiment following a recent memorandum. Furthermore, the second quarter guidance appears not only achievable but also likely to exceed expectations, aided by enhanced visibility and increased upfront buying associated with their expanded product offerings.

Bears say

Doximity is facing a challenging financial outlook due to uncertainty in the economic environment, which has prompted its pharmaceutical clients to revise guidance downward for fiscal years 2023 and 2024. The company's shares are perceived as expensive when compared to its software peers, adding pressure in a context where investor expectations are already high. Furthermore, any failure to meet performance expectations or to increase guidance may lead to increased volatility and could be interpreted negatively by the market.

Doximity (DOCS) has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 37% recommend Buy, 32% suggest Holding, 5% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 19 analysts, Doximity (DOCS) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.